Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)

Enchi Liu; Johan Luthman; Jesse M Cedarbaum; Mark E Schmidt; Patricia E Cole; James Hendrix; Maria C Carrillo; Dorothy Jones-Davis; Erika Tarver; Gerald Novak; Susan De Santi; Holly D Soares; William Z Potter; Eric Siemers; Adam J Schwarz

doi:10.1016/j.jalz.2015.04.001

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001.

Authors

Affiliations

¹ Neuroscience Biomarkers, Discovery, Janssen Research and Development, San Diego, CA, USA. Electronic address: eliu12@its.jnj.com.
² Neuroscience Clinical Development, Clinical Neuroscience Eisai, Woodcliff Lake, NJ, USA.
³ Clinical Development, Biogen, Cambridge, MA, USA.
⁴ Experimental Medicine, Janssen Pharmaceutica NV, Beerse, Belgium.
⁵ Clinical and Translational Science, Imaging, Takeda Pharmaceuticals, Inc, Deerfield, IL, USA.
⁶ Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA.
⁷ Foundation for the NIH, Bethesda, MD, USA.
⁸ Neuroscience Clinical Development, Janssen Research and Development, Titusville, NJ, USA.
⁹ Medical Affairs, Piramal Pharma Inc, Boston, MA, USA.
¹⁰ Clinical Biomarkers, Bristol-Meyer Squibb, Hopewell, NJ, USA.
¹¹ Office of the Director, National Institute of Mental Health, Rockville, MD, USA.
¹² Biomedicines Business Unit, Alzheimer's Disease Platform Team, Eli Lilly and Company, Indianapolis, IN, USA.
¹³ Tailored Therapeutics, Eli Lilly and company, Indianapolis, IN, USA.

PMID: 26194317
DOI: 10.1016/j.jalz.2015.04.001

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board (PPSB) is comprised of representatives of private, for-profit entities (including pharmaceutical, biotechnology, diagnostics, imaging companies, and imaging contract research organizations), and nonprofit organizations that provide financial and scientific support to ADNI through the Foundation for the National Institutes of Health. The PPSB serves as an independent, open, and precompetitive forum in which all private sector and not-for-profit partners in ADNI can collaborate, share information, and offer scientific and private-sector perspectives and expertise on issues relating to the ADNI project. In this article, we review and highlight the role, activities, and contributions of the PPSB within the ADNI project, and provide a perspective on remaining unmet needs and future directions.

Keywords: ADNI; Alzheimer's Disease Neuroimaging Initiative; FNIH; Foundation for the National Institutes of Health; PPSB; Pharmaceutical industry; Private Partner Scientific Board.

Publication types

Review

MeSH terms

Alzheimer Disease / complications
Alzheimer Disease / diagnosis*
Biotechnology
Cognition Disorders / etiology
Consultants*
Drug Industry
Humans
Neuroimaging / methods*
Public-Private Sector Partnerships*
United States